Vandria SA

Vandria discovers and develops novel small molecules that induce mitophagy to treat age-related and chronic diseases. We have patented a range of small molecules that specifically target muscle, the brain, and other tissues. Vandria is at the IND-enabling stage with two lead candidates.

Disease focus:
• CNS: Mild Cognitive Impairment, ALS
• Muscle: Sporadic Inclusion Body Myositis, Sarcopenia
• Other: Inflammatory diseases, immuno-oncology

Vandria seeks: 
1. Investors to broaden its investor base for first clinical trials to begin in Q2 2024  
2. Partners for certain pipeline drugs from its mitophagy platform and a new ferroptosis program